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Staphylococcus aureus bacteraemia (SAB) is commonly complicated by metastatic infection or relapse after treatment. Objectives.
The study aim was to determine the role of bacterial, host, and management factors in development of complicated SAB.Methods.
A prospectively-conducted observational study gathered data on predisposition, management and outcome of 100 consecutive
SAB cases. Antibiotic susceptibilities and genetic lineage of bacterial isolates were determined. Further clinical and microbiological
data were gathered on two retrospective series from 1999–2000 (n = 57) and 2004 (n = 116). Results. In the prospective cases, 27%
met our definition of complicated disease. Expressed as RR and 95% CI, complicated disease was associated with diabetes (1.58,
1.00–2.48), injecting-drug use (5.48, 0.88–33.49), community-onset of symptoms (1.4, 1.02–1.92), and symptom duration ≥ 48
hours prior to starting eﬀective antibiotic therapy (2.10, 1.22–3.61). Uncomplicated disease was associated with the presence of a
central line (0.69, 0.55–0.88) and prompt removal of a primary focus (0.71, 0.57–0.90). Neither methicillin resistance nor genetic
lineage was associated with complicated disease, but methicillin resistance was associated with higher mortality. Conclusions. This
study demonstrates that clinical rather than microbial factors are the major determinants of SAB outcome and underscores the
importance of early treatment.
1. Introduction
Staphylococcus aureus bacteraemia (SAB) is one of the
commonest forms of healthcare associated infection. Among
causes of bacteraemia, S. aureus is notable for how com-
monly it is complicated by the development of secondary
foci of infection and relapse. Reported rates of complicated
disease range from 12.5% to 53% depending on case
definition and the population studied [1–4]. Clinical risk
factors for development of complicated bacteraemia are
well defined and include community onset of disease and
suboptimal medical management [3, 5]. Few data exist on
the importance of microbial factors, other than methicillin
resistance, in determining the outcome of S. aureus infec-
tion. Previous studies have compared strain genotype from
invasive and noninvasive disease [6, 7] but we are aware of
only one previous study assessing the impact of genotype on
outcome of bacteraemia [8]. The aim of this study was to
determine the relative impact of clinical and microbiological
factors on risk of developing complicated SAB.
2. Methods
Brighton and Sussex University Hospitals NHS Trust
(BSUH) is an 820-bed Teaching Hospital with a high
SAB rate. A prospectively conducted observational study
of all new cases of SAB was conducted at BSUH between
August 2006 and May 2007. The sampling time-frame was
determined by the tenure of the trainee microbiologist
running the study. Anonymised clinical data were gathered
from the case notes on the day of the first clinical review and
at a follow-up by the infectious diseases team.
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A retrospective evaluation was also performed of two
cohorts of consecutive SAB cases from which isolates had
been archived as part of a previous unpublished study. The
first consisted of SAB episodes during 1999-2000. The second
consisted of SAB episodes between January and May 2004.
Clinical data were collated from case notes and laboratory
and administrative databases.
3. Ethics Statement
The study was approved by the Brighton and Sussex Univer-
sity Hospital NHS Trust Research and Development oﬃce as
a service evaluation gathering anonymised, routine clinical
data from patient records and not requiring formal ethical
review.
4. Case Definitions
SAB was defined as at least one positive blood culture for
S. aureus. A primary focus of infection was defined as the
likely source of the bacteraemia according to clinician assess-
ment. Complicated bacteraemia was defined as the develop-
ment of either a secondary deep focus of infection (on the
basis of clinical or microbiological evidence) or relapse of
bacteraemia (a second episode of SAB within three months
of the first episode). SAB was considered to be community-
associated using the CDC definition (diagnosis <48 hours of
admission, no previous admission to hospital within twelve
months, no previous MRSA positive cultures, and no long-
term indwelling devices) [9]. Community-onset disease was
defined as SAB diagnosed within 48hrs of admission but not
fulfilling criteria for community-associated disease. All SAB
diagnosed after 48hrs of admission was defined as hospital
onset. Initial antibiotic management was defined as having
been “eﬀective” if the patient received parenteral therapy
with a beta-lactam antibiotic or a glycopeptide (depending
on sensitivities) either alone or in combination with other
agents.
5. Microbiological Analysis
Blood culture isolates were identified as S. aureus on the
basis of colony morphology, Gram’s staining, and a positive
coagulase test. Antibiotic susceptibility was performed by
disk diﬀusion analysis according to British Society for
Antimicrobial Chemotherapy guidelines and vancomycin
minimum inhibitory concentrations (MIC) were determined
by E-test.
Bacterial isolates from the prospective study were geno-
typed using a restriction-modification (RM) test. This
assigns S. aureus isolates to six of the ten major S. aureus
lineages, clonal complex (CC) 1, 5, 8, 22 (corresponding to
MLST 22, predominantly EMRSA-15), 30 (corresponding
to MLST 30 and 36, predominantly EMRSA-16), and 45
(corresponding to MLST 45, 4, and 54) [10, 11]. Briefly, RM
typing exploits the close relationship between variations in
the two hsdS genes and S. aureus lineage. Combinations of
eight primers are used in three PCR reactions to produce
products of diﬀerent sizes [11]. Genes encoding Panton-
Valentine Leukocidin (PVL), Toxic Shock Syndrome Toxin
(tst), and enterotoxins (sea and sej) were sought by PCR
using published primers [12–14].
6. Statistical Analysis
Data were analysed using SPSS 15.0.0 and Minitab 15.
Associations between complicated disease and the variables
described were univariately assessed using the Fisher’s exact
test for proportions and the Mann-Whitney U test for non-
parametric continuous variables. Probability values ≤0.05
were considered significant. For categorical variables the
relative risk (RR) and 95% CI were calculated. Variables sta-
tistically significant in the univariate analysis were analysed
in a multivariate logistic regression model to assess which
were the significant predictors of complicated disease.
7. Results
One hundred SAB cases occurred during the study period.
Fifty-two (52%) were MRSA, equating to an overall rate of
6.68 SAB cases and 3.47 MRSA cases per/10 000 bed days.
The national average MRSA bacteraemia rate for acute trusts
at the start of the study period was 1.77/10 000 bed days
8. Patient Characteristics and
Clinical Management
Fifty-nine (59%) of SAB cases were male and the median
age was 65.5 years. Twenty-seven (27%) fulfilled the criteria
for complicated SAB (Table 1); 24 (24%) had secondary
site infections, 6 (6%) had relapse and 3 had both. On
univariate analysis, complicated bacteraemia was associated
with community-onset disease (RR = 1.4, 95% CI: 1.02–1.92,
P = .018), diabetes mellitus (RR = 1.58, 95% CI: 1.00–2.48,
P = .021), and injecting drug use (IDU) (RR = 5.48, 95%
CI: 0.88–33.49, P = .001). The presence of a central line was
associated with a reduced risk of complicated disease (RR =
0.69, 95% CI: 0.55–0.88 P = .003).
In 77% of cases a primary source of bacteraemia was
apparent. Although the presence or absence of a primary
source did not correlate with complicated disease, removal
of an identified focus within 72 hours was associated with a
lower risk of complicated disease than when the focus was
removed beyond this time or not removed at all (RR = 0.71,
95% CI: 0.57–0.90, P = .006). Bacteraemic patients who
were symptomatic for >48 hours before eﬀective antibiotic
therapy was started were at higher risk of complicated disease
(RR = 2.10, 95% CI: 1.22–3.61, P = .015). There was
no relationship between duration of eﬀective intravenous
therapy <2 weeks and complicated disease (RR = 1.07, 95%
CI: 0.84–1.37, P = .641). The risk of death in patients with
complicated disease was higher (RR = 1.29, 95% CI: 0.99–
1.70, P = .057).
In the multivariate analysis, both forward and backward
likelihood ratio (LR) approaches selected diabetes mellitus,
IDU and Time to Removal of Primary Focus in their final
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Table 1: Clinical Characteristics of 100 cases of S. aureus bacteraemia identified prospectively from 2006 to 2007.
Clinical Characteristics
Total Uncomplicated Complicated
RR 95% CI P
n = 100 n = 73 n = 27
Age
Median 65.5 67 61 — — .386∗
(with IQR) (46–78) (42–77) (49–78) — —
Male Gender 59 (%) 40 (54.8%) 19 (70.4%) 1.28 0.94–1.50 .096
Patient Location
Admission Unit 27(%) 14 (19.2%) 13 (48.1%) 1.56 1.07–2.28 .006
ICU 11(%) 10 (13.7%) 1 (3.7%) 0.78 0.62–0.98 .280
Renal Unit 19(%) 16 (21.9%) 3 (11.1%) 0.84 0.66–1.06 .265
Medical Wards 30(%) 25 (34.2%) 5 (18.5%) 0.82 0.65–1.03 .148
Surgical Wards 13(%) 8 (10.9%) 5 (18.5%) 1.21 0.78–1.90 .329
Community Acquired 7(%) 4 (5.5%) 3 (11.1%) 1.30 0.68–2.49 .384
Community Onset 33(%) 19 (26.0%) 14 (51.9%) 1.40 1.02–1.92 .018
Comorbidities
Diabetes Mellitus 20(%) 10 (13.7%) 10 (37.3%) 1.58 1.00–2.48 .021
IDU 7(%) 1 (1.4%) 6 (22.2%) 5.42 0.88–33.49 .001
Smoker 22(%) 13 (17.8%) 9 (33.3%) 1.30 0.90–1.88 .109
Excess Alcohol 11(%) 9 (12.3%) 2 (7.4%) 0.88 0.65–1.20 .722
HIV 0 0 0 — — —
Haemodialysis 17(%) 14 (19.2%) 3 (11.1%) 0.86 0.67–1.12 .55
Central line in situ 43(%) 38 (52%) 5 (18.5%) 0.69 0.55–0.88 .003
Recent Antibiotics 26(%) 21 (28.8%) 5 (18.5%) 0.87 0.69–1.11 .442
Recent Steroid
Therapy
12(%) 9 (12.3%) 3 (11.1%) 0.97 0.68–1.38 1.000
Recent
Immunosuppression
6(%) 4 (5.5%) 2 (7.4%) 1.10 0.62–1.96 .660
Management
Primary Focus Removed
<72 hours 41(%) 36 (49.3%) 5 (18.5%) 0.71 0.57–0.90 .006
>72 hours/not
removed
36(%) 22 (30.1%) 14 (51.8%) 1.30 0.98–1.74 .061
Not identified 23(%) 15 (20.5%) 8 (29.6%) 1.16 0.83–1.60 .423
Initiation of eﬀective
antibiotics ≥ 48 hours 32 (%) 18 (24.7%) 14 (51.9%) 2.10 1.22–3.61 .015
Duration of IV
treatment >2 weeks
66(%) 47 (64.4%) 19 (70.4%) 1.07 0.84–1.37 .641
Outcome
Mortality (all cause at
30 days)
38/97∗∗
24/73 (32.9%) 14/25∗∗ (56%) 1.29 0.99–1.70 .057
(39.2%)
∗P-value adjusted for ties. ∗∗two patients with complicated bacteraemia were lost to follow up at 30 days.
model, where backward LR also included time to initiation
of eﬀective antibiotics. Diabetes mellitus and IDU were
significant at the 5% level for both approaches with P-values
in the backward LR model of.005 and.004, respectively.
9. Retrospective Study
The two retrospective case series comprised 57 bacteraemias
in 57 patients in 1999-2000 and 116 bacteraemias in 114
patients in 2004 (Table 2). Good quality basic demographic
andmicrobiological data were available on the great majority
of cases but full case notes were available for only 22/57
(38.6%) and 73/116 (62.9%), respectively. The rate of
complicated disease among evaluable patients in the 2004
series (20/73 (27.4%)) was comparable with that found in the
prospective series and higher than that found in the 1999-
2000 series (2/22 (9.1%)) but this did not reach statistical
significance (P = .074). There was a trend towards more
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Table 2: Comparison of clinical characteristics of S. aureus bacteraemia cases identified retrospectively from 1999-2000 and 2004.
Completely evaluable case notes were available for 22 and 73 cases, respectively.
Clinical Characteristics
1999-2000 series 2004 series
P
n = 57 n = 116
Age
Median (interquartile range)∗ 63.1 (53–78) 68.85 (52–80) .23
Male Gender 38 (66.7%) 81 (69.8%) .4
Patient location
Admission unit 8/47 (17.0%) 18/112 (16.1%) .53
ICU 8/47 (17.0%) 19/112 (16.9%) .58
Renal unit 8/47 (17.0%) 26/112 (23.2%) .26
Medical wards 17/47 (36.2%) 32/112 (28.6%) .22
Surgical wards 6/47 (12.8%) 17/112 (15.2%) .45
Community acquired 2/22 (9.1%) 4/73 (5.5%) .42
Community onset 5/22 (22.7%) 21/73 (28.7%) .39
Diabetes Mellitus 2/22 (9%) 20/73 (27.4%) .06
IDU 0/22 (0%) 7/73 (9.6%) .15
Smoker 6/22 (27.3%) 19/73 (26.0%) .55
Central line in situ 10/22 (45.5%) 39/73 (53.4%) .3
diabetes mellitus and intravenous drug use in the 2004 series
compared with the 1999-2000 series, 27.4% versus 9.1% (P =
.06) 9.6% versus 0% (P = .15), respectively.
10. Microbial Analysis
Data on antibiotic sensitivity of the S. aureus isolates were
available on all isolates from the clinical records. The number
of bacteraemias caused by MRSA was 30 (52.6%) in 1999,
69 (59.5%) in 2004, and 52 (52%) in 2006. Forty-five of
patients received vancomycin as treatment for their SAB.
These isolates were all confirmed as vancomycin sensitive
with vancomycin MIC by E-test ranging between 0.75 and
2.0 µg/mL.
Although all 57 isolates for the 1999-2000 series had been
typed, only 36 could be recovered from archives of the 2004
series. From the 100 episodes of bacteraemia in 2006, two
MRSA and one MSSA isolate were not saved, allowing 97
isolates to be typed. No significant changes in the lineages
of S. aureus causing bacteraemia occurred between 1999 and
2006, although the proportion ofMRSA bacteraemias caused
by CC30 (E-MRSA16) increased progressively from 36.6% to
54%, while the contribution of CC22 (E-MRSA15) decreased
from 50% to 38% (Table 3).
Combining data from the retrospective and prospective
series yielded a total of 195 episodes of bacteraemia for
which outcome and antibiotic resistance data were available.
Of these, 109 (55.6%) were MRSA bacteraemias, and 49
(25.1%) were complicated cases. Methicillin resistance was
not associated with complicated disease (25.7% vs. 24.4%,
P = .87) but was associated with excess mortality (46.8%
vs. 30.2%, P = .02). MRSA bacteraemia was associated with
a significant excess of diabetic patients (30.1% vs. 8.3%,
P = .005) and inappropriate initial antibiotic treatment
(40.3% vs. 10.4%, P = .01).
For 152 cases full clinical and typing data were available.
These data show no association between methicillin resis-
tance or staphylococcal lineage and complicated bacteraemia
(Table 4).
Toxin genotyping demonstrated that 3/188 were PVL
positive (1.6%) and other gene frequencies were: tst 83/188
(44.1%), sea 66/188 (35%), and sej 4/188 (2.1%). There were
no diﬀerences in the frequency of these toxin genes between
the three time-series. There was no relationship between
toxin genotype and complicated disease or mortality at three
months. However, all CC30 strains were tst positive and all
four sej positive isolates were of CC5 (Table 5).
11. Discussion
The importance of patient and management factors in
determining outcome of S. aureus bacteraemia is well
established [3, 5]. However, while a wide range of bacterial
toxin and virulence factors is variably present in S. aureus
[15] the relationship between strain variation and outcome
of S. aureus infection is not clear. Peacock et al. reported
an association between seven variable toxin and adhesion
genes and invasive disease [6], while Lindsay et al. found
no association between putative virulence genes and invasive
disease using a microarray approach [7]. Fowler et al.
studied 324 patients with catheter-related SAB and identified
methicillin resistance and the presence of sea as risk factors
for complicated disease [8]. Lalani et al. evaluated the
relationship between bacterial genotype and outcome of
230 episodes of SAB in a phase III clinical trial [16].
In addition to geographical diﬀerences in distribution of
putative virulence factors, relationships between lineage and
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Table 3: Lineages of 190 S. aureus bacteraemia isolates from 1999-2000, 2004, and 2006.
Clonal Complex
MSSA MRSA
1999-20000 2004 2006-2007 1999-2000 2004 2006-2007
N % N % N % N % N % N %
CC22 2 7.4 2 13.3 4 8.5 15 50.0 10 47.6 19 38
CC30 7 25.9 3 20.0 10 21.3 11 36.6 8 38.1 27 54
CC45 6 22.2 3 20.0 11 23.4 0 0 0 0 0 0
CC1 1 3.7 1 6.7 6 12.8 0 0 0 0 4 8
CC8 1 3.7 0 0 5 10.6 2 6.7 0 0 0 0
CC5 3 11.1 0 0 4 8.5 2 6.7 0 0 0 0
Other 7∗ 25.9 6† 40.0 7¶ 14.9 0 0 3∗∗ 14.3 0 0
Total 27 100 15 100 47 100 30 100 21 100 50 100
∗comprising MLSTs 6, 12(x2) 15, 123(x2), and 188, †comprising MLSTs 12, 15, 20, 97, 101, and 123, ¶not MLSTed. ∗∗comprising MLST12 (x3). CC=clonal
complex.
Table 4: Lineages of 152 S. aureus isolates from episodes of uncomplicated and complicated bacteraemia.
Clonal complex
Total Uncomplicated Complicated
RR 95% CI P
n = 152 n = 116 (76.3%) n = 36 (23.7%)
CC30 53 42 (79.2%) 11 (20.8%) 0.94 0.79–1.13 0.689
CC22 39 29 (74.4%) 10 (25.6%) 1.04 0.84–1.28 0.828
CC45 15 11 (73.3%) 4 (26.7%) 1.05 0.76–1.44 0.755
CC1 11 7 (63.6) 4 (36.4%) 1.22 0.77–1.92 0.291
CC8 7 6 (85.7%) 1 (14.3%) 0.88 0.65–1.21 1.00
CC5 7 6 (85.7%) 1 (14.3%) 0.88 0.65–1.21 1.00
Other 20 15 (75%) 5 (25%) 1.02 0.78–1.34 1.00
Table 5: The distribution of toxin genes within the 6 dominant S. aureus lineages.
Clonal Complex Toxin Gene
PVL n = 3 tst-1 n = 83 sej n = 4 sea n = 66
CC30 0 71.1% 0 63.6%
CC22 33.3% 9.6% 0 1.5%
CC45 0 2.4% 0 1.5%
CC1 0 1.2% 0 9.1%
CC8 0 1.2% 0 9.1%
CC5 0 3.6% 100% 6.1%
Other 66.6% 10.8% 0 9.1%
clinical presentation were identified. In this study persistence
of MRSA bacteraemia after treatment was associated with
seg and negatively associated with PVL. Ganga et al. found
a relationship between SCCmec type and outcome in a
study of 253 episodes of SAB, with SCCmec II being an
independent predictor of mortality and SCCmec IVa of
metastatic infection [17].
The population structure of human S. aureus comprises
10 major lineages, or clonal complexes, which have evolved
independently [7]. Exchange of genetic material between
lineages occurs infrequently, probably because of restriction
modification systems [18]. Consequently, if strain diﬀerences
are important in determining whether bacteraemia is com-
plicated by secondary sites of infection or relapse, then this is
likely to be apparent as an association with lineage. However,
in our study of 152 cases of SAB we have found no evidence
of a relationship between lineage and the development of
complicated disease. Nor did we find any association between
complicated disease and the presence of PVL, tst, sea, or sej
toxin genes. The presence of tst gene was strongly related to
CC30 (EMRSA-16) which is consistent with previous studies
[6, 7, 19]. However in contrast to the findings of Holtfreter
et al. who identified 93.3% of sej gene positive bacteraemic
strains in CC8 complex and 6.7% in CC45, we have found
sej only in CC5 [19]. Our results uphold their hypothesis
that superantigen genes have a strong association to clonal
complex, and the most likely explanation for the lineage-
specific diﬀerences relates to geographical variation.
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In contrast with Fowler’s study [8] we have found no
relationship between complicated disease and methicillin
resistance. But, in keeping with previous studies recently sub-
jected to meta-analysis, we have found methicillin resistance
to be associated with excess mortality [20]. This is likely to be
related to higher rates of comorbid disease in these patients,
but could also be due to the increased failure rate of MRSA
therapy compared to MSSA [20].
Reported figures for the rate at which SAB is complicated
by metastatic infection or relapse vary widely between
studies. Fowler et al. reported a relapse rate of 12.7% and
a metastatic infection rate of 30.3% in North Carolina [2].
In contrast, the UK experience of SAB has consistently been
that complicated disease is less common. Among 147 cases
from Birmingham, Das et al. reported relapse and metastatic
infection rates of 6.5% and 7% [21]. Among 815 cases from
Essex, Melzer et al. found a metastatic infection rate of 6.6%
[22]. In our study, rates varied over time. Among the patients
in the 1999-2000 series for whom we were able to get fully
evaluable outcome data, the rate of complicated disease was
only 9.1% compared with 27.4% and 27.0% in the 2004 and
2006 series, respectively. This diﬀerence is likely related to the
small number of diabetics and IDUs in the 1999-2000 series
which could reflect genuine diﬀerences in the clinical work-
load at the trust but should be interpreted with caution since
only a small proportion of cases were evaluable. Another
potential explanation would have been the emergence of a
new virulent clone of S. aureus over time but comparison
of the lineages from 1999, 2004 and 2006 indicates that no
new strain emerged, but that there was a gradual increase of
EMRSA-16 (CC30).
Previous studies have reported increases in vancomycin
MIC to be associated with treatment failure in SAB [23]
however we have found no evidence of raised vancomycin
MIC. Indeed we have previously reported an apparently
paradoxical relationship between the clinical outcome of SAB
and the MIC of vancomycin in these patients [24].
Our study has a number of important limitations. It
is relatively small and from a single centre and thus does
not have the power to detect modest associations between
bacterial lineage and outcome. By being observational,
patients were not subject to a standardised approach of
diagnosis and treatment. For example only 43% of subjects
had an echocardiogram and since follow-up blood cultures
are rarely performed at our institution in the management of
SAB we were unable to assess persistence of bacteraemia on
treatment. For these reasons, we may have underestimated
the number of complicated cases. However, the role of
echocardiography in cases of SAB considered to be at low risk
of endocarditis is controversial [25] and having followed-
up each case for three months, we feel we are unlikely to
have misclassified any complicated cases. In looking at the
role of genotype we have combined our robust prospectively
gathered data with the less complete retrospectively gathered
data set. While being not ideal this has allowed us to more
confidently exclude a major role for bacterial genotype in
determining outcome and is unlikely to have introduced any
significant element of bias. We have classified any second
episode of SAB within three months as a relapse rather than
considering the possibility of reinfection with a diﬀerent
strain. While this could reduce the power of our study to
detect an impact of genotype on outcome, the number of
relapses was small so this is also unlikely to be a significant
eﬀect.
The major strength of our study is that it places the
role of bacterial genotype in the context of clinical factors.
In contrast with the findings of Fowler and Lalani we have
not found a relationship between genotype and outcome
[8, 16]. It is likely this reflects diﬀerences in patient selection,
geographical diﬀerences and sample size. Our failure to find
evidence of a relationship between bacterial genetic factors
and bacteraemia outcome in the 152 cases we have analysed
demonstrates that any impact of microbial factors is likely to
be small compared to the impact of host and management
factors.
The associations we have found, duration of symptoms
prior to adequate antibiotic therapy, delay in removal of a
source of bacteraemia and community onset of symptoms
indicate that duration of bacteraemia is the central deter-
minant of risk of complicated disease. Patients who have
community onset of symptoms, including IDUs are likely to
present later than hospitalised patients. Injecting drug use
and diabetes have been identified by some previous studies as
risk factors for mortality from SAB [26–28]. The only study
we are aware of looking specifically on the impact of diabetes
on SAB found an increased rate of endocarditis compared
with nondiabetic patients but no diﬀerence inmortality [29].
In summary, we have confirmed the previously described
risk factors for complicated SAB; community onset of
symptoms, diabetes mellitus, delay in initiation of eﬀective
antibiotics and failure to identify and remove a primary
focus of infection and failed to identify any role for bacterial
genotype. Our findings underscore the importance of clinical
assessment of patients with SAB for risk of complicated
disease and indicate that clinical rather than bacterial factors
are the major determinants of outcome in this disease.
Acknowledgment
The authors thank Dr Amanda Winn for assistance with the
statistical analysis. This research was funded by the Hospital
Infection Society.
References
[1] S. Lautenschlager, C. Herzog, and W. Zimmerli, “Course and
outcome of bacteremia due to Staphylococcus aureus: evalu-
ation of diﬀerent clinical case definitions,” Clinical Infectious
Diseases, vol. 16, no. 4, pp. 567–573, 1993.
[2] V. G. Fowler Jr., L. L. Sanders, D. J. Sexton, et al., “Outcome
of Staphylococcus aureus bacteremia according to compliance
with recommendations of infectious diseases specialists: expe-
rience with 244 patients,” Clinical Infectious Diseases, vol. 27,
no. 3, pp. 478–486, 1998.
[3] V. G. Fowler Jr., M. K. Olsen, G. R. Corey, et al., “Clinical
identifiers of complicated Staphylococcus aureus bacteremia,”
Archives of Internal Medicine, vol. 163, no. 17, pp. 2066–2072,
2003.
International Journal of Microbiology 7
[4] H. Ringberg, A. Thore´n, and B. Lilja, “Metastatic complica-
tions of Staphylococcus aureus septicemia. To seek is to find,”
Infection, vol. 28, no. 3, pp. 132–136, 2000.
[5] F.-Y. Chang, J. E. Peacock Jr., D. M. Musher, et al., “Staphy-
lococcus aureus bacteremia: recurrence and the impact of
antibiotic treatment in a prospective multicenter study,”
Medicine, vol. 82, no. 5, pp. 333–339, 2003.
[6] S. J. Peacock, C. E. Moore, A. Justice, et al., “Virulent combi-
nations of adhesin and toxin genes in natural populations of
Staphylococcus aureus,” Infection and Immunity, vol. 70, no. 9,
pp. 4987–4996, 2002.
[7] J. A. Lindsay, C. E. Moore, N. P. Day, et al., “Microarrays reveal
that each of the ten dominant lineages of Staphylococcus aureus
has a unique combination of surface-associated and regulatory
genes,” Journal of Bacteriology, vol. 188, no. 2, pp. 669–676,
2006.
[8] V. G. Fowler Jr., A. Justice, C. Moore, et al., “Risk factors
for hematogenous complications of intravascular catheter-
associated Staphylococcus aureus bacteremia,” Clinical Infec-
tious Diseases, vol. 40, no. 5, pp. 695–703, 2005.
[9] R. M. Klevens, M. A. Morrison, J. Nadle, et al., “Invasive
methicillin-resistant Staphylococcus aureus infections in the
United States,” Journal of the American Medical Association,
vol. 298, no. 15, pp. 1763–1771, 2007.
[10] E. J. Feil, J. E. Cooper, H. Grundmann, et al., “How clonal is
Staphylococcus aureus?” Journal of Bacteriology, vol. 185, no.
11, pp. 3307–3316, 2003.
[11] J. D. Cockfield, S. Pathak, J. D. Edgeworth, and J. A. Lindsay,
“Rapid determination of hospital-acquiredmeticillin-resistant
Staphylococcus aureus lineages,” Journal of Medical Microbiol-
ogy, vol. 56, no. 5, pp. 614–619, 2007.
[12] S. Jarraud, C. Mougel, J. Thioulouse, et al., “Relationships
between Staphylococcus aureus genetic background, virulence
factors, agr groups (alleles), and human disease,” Infection and
Immunity, vol. 70, no. 2, pp. 631–641, 2002.
[13] K. Becker, R. Roth, and G. Peters, “Rapid and specific
detection of toxigenic Staphylococcus aureus: use of two
multiplex PCR enzyme immunoassays for amplification and
hybridization of staphylococcal enterotoxin genes, exfoliative
toxin genes, and toxic shock syndrome toxin 1 gene,” Journal
of Clinical Microbiology, vol. 36, no. 9, pp. 2548–2553, 1998.
[14] H.-Y. Tsen and T.-R. Chen, “Use of the polymerase chain
reaction for specific detection of type A, D and E enterotox-
igenic Staphylococcus aureus in foods,” Applied Microbiology
and Biotechnology, vol. 37, no. 5, pp. 685–690, 1992.
[15] R. J. Gordon and F. D. Lowy, “Pathogenesis of methicillin-
resistant Staphylococcus aureus infection,” Clinical Infectious
Diseases, vol. 46, supplement 5, pp. S350–S359, 2008.
[16] T. Lalani, J. J. Federspiel, H. W. Boucher, et al., “Associations
between the genotypes of Staphylococcus aureus bloodstream
isolates and clinical characteristics and outcomes of bac-
teremic patients,” Journal of Clinical Microbiology, vol. 46, no.
9, pp. 2890–2896, 2008.
[17] R. Ganga, K. Riederer, M. Sharma, et al., “Role of SCCmec
type in outcome of Staphylococcus aureus bacteremia in a
single medical center,” Journal of Clinical Microbiology, vol. 47,
no. 3, pp. 590–595, 2009.
[18] D. E.Waldron and J. A. Lindsay, “Sau1: a novel lineage-specific
type I restriction-modification system that blocks horizontal
gene transfer into Staphylococcus aureus and between S. aureus
isolates of diﬀerent lineages,” Journal of Bacteriology, vol. 188,
no. 15, pp. 5578–5585, 2006.
[19] S. Holtfreter, D. Grumann, M. Schmudde, et al., “Clonal
distribution of superantigen genes in clinical Staphylococcus
aureus isolates,” Journal of Clinical Microbiology, vol. 45, no.
8, pp. 2669–2680, 2007.
[20] M. H. Kollef, “Limitations of vancomycin in the management
of resistant staphylococcal infections,” Clinical Infectious Dis-
eases, vol. 45, supplement 3, pp. S191–S195, 2007.
[21] I. Das, N. O’Connell, and P. Lambert, “Epidemiology, clinical
and laboratory characteristics of Staphylococcus aureus bac-
teraemia in a university hospital in UK,” Journal of Hospital
Infection, vol. 65, no. 2, pp. 117–123, 2007.
[22] M. Melzer, S. J. Eykyn, W. R. Gransden, and S. Chinn, “Is
methicillin-resistant Staphylococcus aureus more virulent than
methicillin-susceptible S. aureus? A comparative cohort study
of British patients with nosocomial infection and bacteremia,”
Clinical Infectious Diseases, vol. 37, no. 11, pp. 1453–1460,
2003.
[23] A. Soriano, F. Marco, J. A. Martinez, et al., “Influence
of vancomycin minimum inhibitory concentration on the
treatment of methicillin-resistant Staphylococcus aureus bac-
teremia,” Clinical Infectious Diseases, vol. 46, no. 2, pp. 193–
200, 2008.
[24] J. Price, S. Atkinson, M. Llewelyn, and J. Paul, “Paradoxical
relationship between the clinical outcome of Staphylococcus
aureus bacteremia and the minimum inhibitory concentration
of vancomycin,” Clinical Infectious Diseases, vol. 48, no. 7, pp.
997–998, 2009.
[25] A. L. Sullenberger, L. S. Avedissian, and S. M. Kent, “Impor-
tance of transesophageal echocardiography in the evaluation
of Staphylococcus aureus bacteremia,” Journal of Heart Valve
Disease, vol. 14, no. 1, pp. 23–28, 2005.
[26] P. C. Hill, M. Birch, S. Chambers, et al., “Prospective study of
424 cases of Staphylococcus aureus bacteraemia: determination
of factors aﬀecting incidence and mortality,” Internal Medicine
Journal, vol. 31, no. 2, pp. 97–103, 2001.
[27] L. E. Wilson, D. L. Thomas, J. Astemborski, T. L. Freedman,
and D. Vlahov, “Prospective study of infective endocarditis
among injection drug users,” Journal of Infectious Diseases, vol.
185, no. 12, pp. 1761–1766, 2002.
[28] J. M. Mylotte and A. Tayara, “Staphylococcus aureus bac-
teremia: predictors of 30-day mortality in a large cohort,”
Clinical Infectious Diseases, vol. 31, no. 5, pp. 1170–1174, 2000.
[29] G. Cooper and R. Platt, “Staphylococcus aureus bacteremia
in diabetic patients. Endocarditis and mortality,” American
Journal of Medicine, vol. 73, no. 5, pp. 658–662, 1982.
